Novartis faces patent expiry for its mainstay drug this summer,

How will Swiss company Novartis, which faces the US patent expiry of its flagship drug Entresto in July this year, counter a decline in sales of more than 1.2 trillion yen? Analysis. A misjudgment is likely to lead to a situation where the company runs out of arrows and breaks its sword in the cardiovascular field.